Tiffany Aldrich News Today : Breaking News, Live Updates & Top Stories | Vimarsana

First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U S ) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U S ), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk

First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U S ) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U S ), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Tiffany aldrichWolfgang schiessl europeDaiichi sankyo europeOliver appelhansDaiichi sankyo europe gmbAlberico catapanoDaiichi sankyoSheldon koenigHead of europe specialty divisionExchange commissionEuropean commissionEsperion therapeutics incUniversity of milanOral treatmentEzetimibe fixed dose combinationReceive label update approval

Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia

ANN ARBOR, Mich., May 20, 2024 Esperion and Otsuka Pharmaceutical Co., Ltd announced today that the primary endpoint was achieved in the Phase 3 trial in Japan for bempedoic acid as a.

United statesTiffany aldrichOtsuka pharmaceutical co ltdEsperion therapeutics incExchange commissionEsperion therapeuticsAdverse eventContact information

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Tiffany aldrichEquity incentiveEquity incentive planContact information

Esperion Reports First Quarter 2024 Financial Results

– Q1 Total Revenue Grew 467% Y/Y to $137.7 Million, Reflecting Strong Growth Globally – – Q1 U.S. Net Product Revenue Grew 46% Y/Y to $24.8 Million – – Q1 Retail Prescription Equivalents.

Czech republicTiffany aldrichDaiichi sankyo europeSheldon koenigEsperion therapeutics incEuropean commission decision for expanded labelsNational health insuranceExchange commissionEuropean commissionEuropean medical agencyDaiichi sankyo companyCommittee for medical products human useRevenue grewReflecting strong growth globallyProduct revenue grewPrescription equivalents grew

Esperion to Participate in Upcoming May Investor

ANN ARBOR, Mich., April 29, 2024 (GLOBE NEWSWIRE) Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following.

United statesLas vegasTiffany aldrichHealth care conference in las vegas onSecuritie life sciences conferenceLife sciences conferenceNew yorkAmerica securitieCare conferenceAnnual bioconnect investor conferenceContact informationNasdaq esprEsperion therapeutics